Trulieve on the NYSE: The Listing Is Real, the Buy Case Isn't That Simple

The competitor headline says Trulieve is a buy because it's now the first plant-touching cannabis operator on the New York Stock Exchange. Historic milestone, sure. But the stock has fallen 26% since the NYSE bells rang on June 10, and the latest earnings report carries a $406 million net loss. That loss looks like a reason to run — or, depending on how closely you look at what actually happened, it looks like exactly the kind of accounting noise the market overreacts to.

I need to sort through which one it is.

What the $406 million loss actually is — and isn't

Trulieve's Q2 2026 report showed a GAAP net loss of $406 million, driven almost entirely by a $403.3 million charge from the deconsolidation of its Harvest subsidiary. Harvest held the company's mixed medical-and-adult-use operations in states like Maryland, Ohio, and Arizona. The deconsolidation wasn't a business failure — it was a deliberate restructuring. To qualify for the NYSE listing, Trulieve had to separate its adult-use operations from the consolidated financial statements. The exchange still won't allow a company to consolidate U.S. recreational cannabis on its books.

So Trulieve moved those operations into a separate entity, Harvest Enterprises LLC, and walked away with approximately 90% economic interest through non-voting units. Those units convert to full voting ownership once a "Stock Exchange Permissibility Date" occurs — essentially, once the NYSE changes its rules to allow adult-use consolidation. That's a free call option on the entire U.S. recreational market, sitting in Trulieve's balance sheet.

The $403.3 million charge is non-cash and one-time. Excluding it, Trulieve reported adjusted net income of $20 million, adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization — a rough proxy for operating cash generation) of $98 million, and a gross margin of 60%. That's not a business collapsing. It's a business that took a haircut to its consolidated top line in exchange for clean financials and a blue-chip listing.

The valuation that remains

At $8.75 per share, Trulieve's market cap sits at $1.69 billion. The stock trades at roughly 1.48 times trailing revenue and 6.9 times trailing free cash flow. Free cash flow itself grew 176% year-over-year to $186 million over the last twelve months, while operating cash flow came in at $244 million. The company holds $325 million in cash.

Those cash flow numbers are arguably the most underappreciated part of the story. A company generating $186 million in free cash flow on $1.15 billion in annualized revenue is running an FCF margin near 16%. In a sector where most peers burn cash, that stands out.

But here's where the setup gets more complicated.

The revenue trajectory isn't growth — it's contraction

The competitor title doesn't need to mention this, but the persona framework demands it: Trulieve's revenue is declining. Q2 revenue of $271 million was down 10% from Q2 2025. Q1 was down 4%. Full-year 2025 revenue was flat at $1.18 billion versus 2024. The growth engine has stalled.

Q3 guidance of approximately $222 million confirms a structural step-down, not a temporary blip. That's what the post-Harvest medical-only company looks like on the top line. Management projects full-year 2026 cash flow from operations of at least $225 million — down from the prior $250 million target — and capital expenditures up to $95 million, with the incremental spend earmarked for emerging medical markets in Georgia and Texas.

This matters because the core GARP thesis — valuation compression relative to growth rate — requires growth. You can't label a stock a value buy if revenue is declining and the forward revenue guidance points further down. The 60% gross margins are excellent, and the medical-only footprint (206 dispensaries, 3.5 million square feet of DEA-registered production capacity) is defensible. But margins alone don't drive multiple expansion in a shrinking top-line environment.

The Schedule III tailwind

The one genuinely transformative catalyst is the April 2026 rescheduling of medical marijuana to Schedule III. This removes the punitive IRC Section 280E tax treatment that previously forced cannabis operators to pay effective tax rates of 70% or more, because they couldn't deduct ordinary business expenses. For a medical-only operator like the post-Harvest Trulieve, the path to tax normalization is now open. The company has already filed to register with the DEA.

More interestingly, Trulieve carries a $598 million uncertain tax position liability on its balance sheet. If retroactive relief is granted for pre-rescheduling periods — something the company's own tax advisors have signaled as possible — that liability could partially or fully reverse, creating a massive one-time earnings boost. That's not guaranteed, and the timeline is uncertain, but it's optionality that the market isn't pricing in at 1.48x sales.

The moat under stress

Florida remains Trulieve's fortress. The company operates the dominant dispensary network in the state, where it benefits from a medical-only framework that locks out adult-use competition and provides pricing power. The geographic expansion into Georgia — where the company has already begun shipping medical cannabis to pharmacies — and the push into Texas represent the secular growth path. But these are still early-stage markets. Georgia's program hasn't launched retail sales yet, and Texas is even further out.

The moat holds for now. But it's a defensive moat, not an offensive one.

What about price action?

The stock has lost 26% year-to-date, pulling back from a 52-week high of $12.30 to the current $8.75 level. The RSI sits at 45.8, neither oversold nor overbought. The MACD is negative, reflecting the post-listing decline. Volatility is elevated at 6.4% over 20 days. The stock opened below its previous close today, adding another 2.8% in losses.

There's no clear bear trap forming yet — no volume exhaustion, no reversal structure, no sign that selling pressure has run out. The 26% decline is real selling, not just a gap-and-fade.

The verdict

The competitor title isn't wrong to flag Trulieve as interesting. The FCF generation is strong, the 280E tax relief is transformative, the Harvest conversion option is valuable, and the 1.48x sales multiple looks cheap for a company with 60% gross margins and $325 million in cash. AInvest's aggregate signal labels the stock a Buy.

But the title is wrong about the urgency. The declining revenue trajectory, the Q3 guidance that confirms a structural step-down, and the absence of a clear near-term growth catalyst make this a watch zone, not a conviction entry. The better risk/reward is likely on a deeper pullback toward the $7.80-8.00 range or when price action signals that selling exhaustion has set in.

I'd categorize this as a Hold with a buy-on-weakness posture. The fundamental setup — cash generation, margin profile, Schedule III tailwind, and Harvest optionality — supports a long-term bull case. But the market isn't panicking right now, and there's no reason to force an entry into a revenue-contracting business when the price action hasn't confirmed a lower-risk setup.

Reassess if the stock breaks above $10 with volume confirmation, or if Georgia or Texas regulatory approvals accelerate the growth timeline enough to turn the top-line trajectory positive. Until then, let the setup come to you.